OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2020-12-31-accounts

Working together to improve care and outcomes

Intensive Care National Audit and Research Centre Annual Report and Accounts | Year ended 31 December 2020

www.icnarc.org

About ICNARC

In the UK, each year, around 184,000[1] people are admitted to an adult general critical care unit.

At the Intensive Care National Audit and Research Centre (ICNARC), we work to ensure the best possible critical care by facilitating improvements in the structure, process, outcomes and experiences - for patients and for those who care for them.

We achieve this by developing and sharing information about the quality of critical care to those who finance, commission, manage, deliver and experience critical care (both within and outside the NHS) through our national clinical audit and through our national and international research.

Improving care and outcomes

At ICNARC, we believe that quality critical care has three main elements:

To find out more about ICNARC, please visit www.icnarc.org

1 Overall number of admissions to adult general critical care units in UK, excluding admissions to adult specialist, paediatric or neonatal critical care units.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 2

Contents

Statement of Trustees’ responsibilities Independent auditors’ report to the Trustees of the Intensive Care National Audit and Research Centre

Financial statements

Balance Sheet Statement of Cash Flows Notes to the Accounts

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 3

Message from the Chair

Despite careful, organisation-wide, business planning, the objectives within the 2020 Business Plan were all but abandoned in late January as ICNARC stepped up to play its role in the impending UK epidemic of COVID-19.

With creative vision and strong leadership, Kathy identified two important roles for ICNARC to support those planning, organising and delivering critical care for patients with COVID19 – (1) monitoring and reporting epidemiology and outcomes and (2) managing research evaluating new and existing therapies in randomised clinical trials.

As Director, Kathy led a highly professional response – adapting rapidly to the new and changing roles for ICNARC. Within days, all aspects required had been actioned. The new roles translated into high workload and, following a rapid appraisal, ICNARC staff were redirected to support the COVID-19 response. At the same time, a working from home policy was implemented, ahead of the national lockdown on 23 March 2020.

Kathy worked indefatigably to lead and support colleagues to provide high-quality, timely and comprehensive analyses to provide the NHS with unrivalled information about the impact of COVID-19 on critical care and to help clinicians, both nationally and internationally, working together to evaluate therapies for COVID-19.

Rapid provision and wide dissemination of timely, transparent, responsible and responsive information and the secure sharing of critical care data to support further learning about COVID-19 were a credit to Kathy’s leadership and to the commitment from all ICNARC staff. ICNARC more than delivered on the original vision intended by those involved in its establishment back in January 1994. The Trustees and I are extremely proud of all achieved and of the reputation of ICNARC which has grown immeasurably as a result.

Message from the Director

I start this message by paying huge tribute to all our colleagues/friends working in critical care teams across the UK (and internationally). Their heroic response to, and dedicated care for, the unprecedented numbers of people becoming critically ill with COVID-19 (and for their loved ones), in such extreme conditions, was and continues to be humbling. Thank you.

As we reach the end of 2020, I am so very proud of ICNARC and the role it played this year in supporting critical care, nationally and internationally. ICNARC is its staff and every individual member of staff (including those who joined us during 2020 – in these strange circumstances of virtual working) played their part in our response. ICNARC stepped-up to meet the additional challenges of COVID-19 and met them with the speed needed, and dictated by, the ever-increasing numbers of patients becoming critically ill with COVID-19.

Leadership, at a senior level, was vital. I would like to acknowledge the key roles played by the Senior Management Team – David Harrison (Head Statistician), Paul Mouncey (Head of Research) and Tracey Harrison/Jane-Eve Straughton (Head of Operations) – in sharing in the leadership and delivery of the important work on COVID-19 from ICNARC.

It is a real credit to all ICNARC staff members that not only did we deliver on our activities around COVID-19 but business-as-usual continued with: ongoing improvements to our operational infrastructure/systems; successful awarding of new research grants; and targets met across our research studies and our national clinical audits.

Finally, I pay tribute to those who shared the original vision for ICNARC and to all those who helped it develop over the years into an agile organisation able to share important information so rapidly and so rigorously…

Kathy Rowan I Director

Sue James | Chair

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 4

Strategic report

Charitable Objects

“…the advancement of education in the organisation and practice of critical care (in particular, through the promotion of audit and research into critical care and the publication of the useful results of such audit and research)…”.

“… research is concerned with discovering the right thing to do; audit with ensuring that it is done right …”

Richard Smith, former Editor-in-Chief, British Medical Journal

We achieve our Charitable Objects by…

…establishing quality through research

Read more about the important role ICNARC played in identifying effective care for patients critically ill with COVID-19 (page 8)

…assessing quality through audit

Read more about the important role ICNARC played in monitoring care and outcomes for patients critically ill with COVID-19 (page 11)

…promoting quality through sharing information Read more about how we rapidly analysed data and shared information, nationally and internationally, on patients critically ill with COVID-19 (page 14)

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 4

COVID-19

In late 2019, an outbreak of a novel zoonotic coronavirus infection (severe acute respiratory syndrome coronavirus 2) began to emerge in humans with its epicentre in Wuhan, China.

On 30 January 2020, the WHO indicated a Public Health Emergency of International Concern. On 11 February 2020, the WHO announced “COVID-19” as the name for this new disease and, on 11 March 2020, the WHO declared a COVID-19 pandemic. The first cases of COVID-19 were reported in the United Kingdom (UK) in late January 2020.

To help inform planning of critical care services, both centrally and locally, ICNARC was well placed to rapidly collate, analyse and report data, weekly, on patients critically ill with confirmed COVID-19 by virtue of its ongoing co-ordination of the Case Mix Programme, the national clinical audit for adult critical care covering England, Wales and Northern Ireland.

To help support evaluation of therapeutic interventions to combat the challenge of COVID-19, both nationally and internationally, ICNARC was well placed to manage and co-ordinate research on patients critically ill, or likely to become critically ill, with COVID-19 by virtue of its ongoing UK co-ordination of the global Randomised Embedded Multifactorial Adaptive Platform trial for Community Acquired Pneumonia (REMAP-CAP) redirected to COVID-19.

Responding to the global pandemic (UK epidemic), in the above two ways, was the major focus of ICNARC’s actual activities in 2020.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 5

Progress against priorities for 2020

Three key themes underpin our priorities:

Work across all regions and nations of the UK and internationally

Diversify to embrace new methods and areas

Inspire, and be inspired by, the critical care community and ensure that what we do is what they need

Work across all regions and nations of the UK and internationally

Diversify to embrace new methods and areas

Inspire, and be inspired by, the critical care community and ensure that what we do is what they need

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 6

Five important enablers underpin our priorities:

Governance

People and culture

Communication

Financial sustainability

Technology

Governance

People and culture

Communication

Financial sustainability

Technology

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 7

Establishing quality through research

Research at ICNARC is conducted within our Clinical Trials Unit (CTU), a fully registered unit by the UK Clinical Research Collaboration. Our small CTU conducts a broad portfolio of research in critical care, both experimental (randomised clinical trials) and observational studies, applying quantitative and qualitative methods. We evaluate the care, outcomes and experiences of the critically ill with a view to informing best care, outcomes and experiences for future patients.

International Expert Panel, UK Clinical Research Collaboration

Research – 2020

Development of our research portfolio continued in adult and paediatric critical care.

Adult critical care research

Paediatric critical care research

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 8

Research highlights – 2020

REMAP-CAP for COVID-19

Steroids – hydrocortisone

Interleukin 6 receptor antagonists

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 9

Our plans for research – 2021

To find out more about ICNARC’s research, please visit: - www.icnarc.org/our research/about

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 10

Assessing quality through audit

Audit at ICNARC is conducted within our National Audit Programme. Through specification, management and analysis of accurate clinical audit data and from applying accurate risk prediction, we support health care providers to benchmark their care and outcomes with other providers to prompt quality improvement.

Professor Sir Nick Black, ex-Trustee, ICNARC

National Audit Programme

Our National Audit Programme currently encompasses four national clinical audits, with three operating within the NHS and registered on the NHS Quality Accounts.

Launched in 1994 (the foundation for ICNARC), the Case Mix Programme is the national clinical audit of patient outcomes from adult critical care – covering adult, general critical care units (combined intensive/high dependency care units) within and outside the NHS in England, Wales and Northern Ireland.

Launched in 2009 in collaboration with the Resuscitation Council (UK), the National Cardiac Arrest Audit is the national clinical audit of patient outcomes following in-hospital cardiac arrest in the UK.

Launched in 2010 in collaboration with the National Office of Clinical Audit in Ireland, the Irish National Intensive Care Unit Audit is the national clinical audit of patient outcomes from adult critical care units in the Republic of Ireland.

Launched in 2014 in collaboration with the Association for Cardiothoracic

Anaesthesia and Critical Care, the Assessment of Risk in Cardiothoracic Intensive Care is the national clinical audit of patient outcomes from adult cardiothoracic critical care units in the UK.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 11

Audit highlights – 2020

Case Mix Programme

National Cardiac Arrest Audit

Irish National Intensive Care Unit Audit (INICUA)

Assessment of Risk in Cardiothoracic Intensive Care (ARCtIC)

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 12

Our plans for audit – 2021

To find out more about ICNARC’s audit, please visit: - www.icnarc.org/our audit/about

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 13

Promoting quality through sharing information

We share information – results from our national clinical audits and from our research studies – through local, regional and national reporting (audit) and through peer-reviewed scientific and other publications (research). We enhance our dissemination activities for our audit and research information through digital media and through presentations at local, regional, national and international meetings/conferences – both at our own and others’ events.

We endeavour to ensure that relevant information reaches those experiencing, delivering, managing, commissioning and financing critical care in the UK. We believe that critical care should be based on rigorous, scientific evidence.

In 2020, our focus was on COVID-19…

Sharing information highlights – 2020

To help inform planning of critical care services, both centrally and locally, ICNARC, was well placed to rapidly collate, analyse and report data on patients critically ill with confirmed COVID-19. Commencing in March 2020, reports on patients critically ill with confirmed COVID-19 were sent daily to senior colleagues within the NHS and weekly reports describing epidemiology and outcomes were disseminated widely, both directly to relevant individuals and indirectly, online, via the ICNARC website. Information generated by Meltwater, a global media monitoring company, indicated that – at the height of the first “wave” of the UK epidemic – the potential reach of ICNARC’s weekly reports on patients critically ill with confirmed COVID-19 was 4.6 billion (of a 2020 total world population of 7.8 billion). Potential reach being an estimation of the number of different people potentially exposed to the media article reporting on data from the ICNARC COVID-19 report.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 14

In addition to routine daily and weekly reporting, rapid ad hoc reports were prepared in response to specific requests from policymakers involved in planning of critical care services. Descriptive and risk-adjusted reports were disseminated, directly, to individual critical care units and networks. Important scientific information was also shared by ICNARC in preprints and in peer-reviewed scientific publications.

To help support evaluation of therapeutic interventions to combat the challenge of COVID-19, both nationally and internationally, ICNARC was well placed to manage and co-ordinate research on patients critically ill, or likely to become critically ill, with COVID-19. Important information on the effectiveness of new or existing therapies, generated from the global REMAP-CAP trial (redirected to COVID-19), were shared in peer-reviewed scientific publications.

COVID-19 outputs

Other (non-COVID-19) sharing of important information from our Research and Audit activities also continued throughout 2020. With respect to research, publications, from studies on our broad portfolio of research were accepted for publication in the scientific, peer-reviewed literature. With respect to audit, critical care units (including networks of units) and hospitals participating in our national clinical audits continued to receive their quarterly quality reports. Five dataset workshops were held.

Other (non-COVID-19) outputs

Digital communications

Twitter – our followers more than doubled to 7690 in 2020 (from 3,020 in 2019) with 93 ICNARC Tweets generating 1,523,500 impressions.

Our plans for sharing information – 2021

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 15

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 16

Trustees Report

Financial review

The Board of Management (Trustees) has adopted the provisions of the Statement of Recommended Practice (SORP) Accounting and Reporting by Charities (FRS 102) in preparing ICNARC’s financial statements.

· Income

ICNARC is funded by our subscription-based national clinical audits and by successful awarding of research grants.

For the year ended 31 December 2020, ICNARC generated total income of £3,852,361, An increase of 41% on 2019.

Income includes £2,236,346 from audit subscriptions/activities, £1,582,809 from research grants and £33,205 from other data services.

Primary sources of income are subscriptions from participants, primarily NHS Trusts, participating in our national clinical audits and from research grants awarded by government and other funding bodies to conduct our research studies. In 2020, we also received income related to auditing, reporting and analyses to inform and support the COVID-19 pandemic.

We recognise the need to build our reserves to enable investment in improving our technology and security and to manage the impact of unplanned events.

The Board of Management (Trustees) has a reasonable expectation that ICNARC has sufficient resources and control mechanisms to continue operating for the foreseeable future and believes that there are no material uncertainties that call into doubt the ability of ICNARC to continue as a going-concern.

The financial impact of the COVID-19 pandemic on income has been reviewed and the projected cash flow, for the 24 months to December 2022, confirms that ICNARC has sufficient income to meet expenditure for the immediate and longerterm future. There has been no need to access ICNARC’s reserves during the pandemic period.

Remuneration

The salaries of ICNARC staff are periodically benchmarked against similar roles within organisations that engage in similar activities. ICNARC aims to set salaries as close to the median as possible in order to attract highlyqualified staff. All roles are evaluated against agreed organisational criteria that determine the grade and salary for the role.

· Expenditure

Total expenditure in 2020 is £3,618,054, an increase of 32% on 2019.

· Cash

At the end of the financial year, total cash is £1,205,133. This is a decrease of 16% on 2019 and is attributed to the timing of grant agreements and receipts.

· Funds Carried Forward

Funds carried forward at the end of the financial year are £904,842. This is an increase of 35% against the funds carried forward at the end of 2019.

Going concern

ICNARC is well-placed to manage the business risks we face. This position is supported by a strong cash flow and proven ability to win new research grants.

Key risks and uncertainties

The Board of Management (Trustees) has identified and reviewed the major risks to which ICNARC is exposed and established systems and procedures to manage those risks. This involves identifying potential risks and then assessing the likelihood of their occurrence and impact.

Where systems are already in place to mitigate these risks, schedules for regular monitoring and review have been adopted. Where systems are not already in place, deadlines have been set for their development by staff for approval by the Board of Management (Trustees).

Day-to-day management of the risks is delegated to the Director along with other members of the Senior Management Team (SMT) and these risks are reviewed regularly during the usual course of business.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 17

The Board of Management (Trustees) considers the following to be the key risks on which ICNARC needs to focus:

· Insufficient financial resources

Risk : Significant deterioration in economic climate and public sector funding pressures resulting in reduction in income – UK and EU.

Mitigation: We continue to plan our budget to ensure that we obtain at least full cost-recovery, and we aim to maintain sufficient reserves to cover short-term income downturns and support future investment. We achieve this by focusing on diversifying our income to have a mixed portfolio of funders, balanced with efficiency savings which are underpinned by robust financial management.

· COVID-19 pandemic

Risk : The ongoing global pandemic/UK epidemic has the potential to impact income and expenditure.

Mitigation: While non-COVID-19 research studies were temporarily paused in 2020, ICNARC’s key role in analysing and reporting data during the pandemic has ensured sufficient income levels have been maintained to cover expenditure. We are also further diversifying our income streams through developing our engagement with key international projects and expanding data linkages to new and established data havens.

Reserves

· Knowledge and skills

Risk: Attracting and retaining staff with management, scientific and information technology expertise as these are strategically important in ensuring that ICNARC remains a leading organisation in emergency and critical care audit and research.

Mitigation: We manage this risk through a programme of mentoring and supporting key management, scientific and information technology staff, developing skills/expertise and reviewing our employment package for all staff.

· Technology and data security

Risk: Our technology underpins and powers our data upload, processing and reporting for our national clinical audits and for our research studies. The ability to keep pace with, and update, our technology and to ensure that we adopt the necessary and appropriate security requirements, presents an ongoing challenge as we strive to embrace new and more efficient, digital technologies.

Mitigation: We have increased our investment in Technology and Information Governance expertise and continue to maintain our Section 251, DSP Toolkit and Cyber Essentials compliance. We conduct regular penetration tests and are working closely with our managed services and our customers to ensure that we are adopting the best systems and processes to mitigate technology and data security risks.

The Board of Management (Trustees) has a policy whereby unrestricted funds, not committed or invested in tangible fixed assets (the free reserve), held by the organisation should be between 25% and 50% of the annual resource expended in the General Fund.

At this level, the Board of Management (Trustees) feels that, in the event of a significant drop in funding due to any external/internal event(s) or fraudulent activity, ICNARC would still be able to continue current activities until new funding was secured. In 2020, the annual surplus of £234,308 allowed us to continue to make critical investments in our IT platform whilst also maintaining sufficient reserves to fall within our free reserve target.

The General Fund, totalling £570,474 at the end of 2020, is equivalent to 35% of the annual resource expended in the General Fund during the year. This is after increasing the designated Development Fund by £400,000 during the year. In June 2020, the Board of Management (Trustees) reviewed the Reserves Policy to ensure that it was fit-for-purpose. The Board of Management (Trustees) has reviewed the level of reserves and concluded that the level of reserves is appropriate.

The budget for 2021 financial year indicates a small surplus which, if achieved, will be added to the General Reserve and remain within the Board’s policy target.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 18

Fundraising

ICNARC does not raise funds from the public and no fundraising activities have been undertaken either by ICNARC or by other fundraisers on behalf of ICNARC.

Auditors

MHA MacIntyre Hudson is deemed to be re-appointed under section 487(2) of Companies Act 2006.

Status

The Company is a Registered Charity (1039417) and is exempt from income and corporation taxes under S466 Corporation Tax Act 2010 (CTA 2010).

Special exemptions

This Report of the Directors and Board of Management (Trustees) has been prepared in accordance with the special provisions under Part 15 of the Companies Act 2006 relating to small companies.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 19

Governance, structure and management

The Intensive Care National Audit and Research Centre (ICNARC) is a Company Limited by Guarantee incorporated in England on 8 July 1994 and governed by its Memorandum and Articles of Association.

ICNARC’s Articles of Association provide for a limitation of member liability to £1. ICNARC is a Registered Charity in England and Wales.

Registered Name of Company:

Intensive Care National Audit and Research Centre Company Number: 02946727 Registered Charity Number: 1039417 Registered Office: Napier House, 24 High Holborn, London WC1V 6AZ

Our Trustees

The Trustees form the Board of Management and are responsible for the governance and strategy of ICNARC. The Board of Management is made up of eleven Trustees, comprising a mix of health care and other professionals. The Board of Management (Trustees) has full legal responsibility for the actions of ICNARC. Trustees are appointed for a renewable term of three years and are the Directors of the Company for the purposes of the Companies Act 2006.

The Board of Management (Trustees) meets four to five times per year and delegates the day-today responsibility for running ICNARC to the Director, along with other members of the Senior Management Team (SMT). In 2018, an Audit & Risk Committee was established to assist the Board of Management (Trustees) in its duty to supervise the broad direction of ICNARC’s financial affairs and to ensure compliance with Company Law and Charity Commission best practice. The Board of Management (Trustees) acts as advisors to staff on business, health care and other issues and keeps the organisation upto-date with developments within health care and other relevant fields. All Trustees give their time freely and no Trustee remuneration was paid in 2020.

The Trustees serving during 2020 and into 2021 are:

Chair: Ms Susan James Trustees: Dr Simon Baudouin Dr Tim Gould Dr Lisa Hinton Mr Paul Maddox (Treasurer) Prof David Menon Ms Carolyn Seet Dr Gareth Sellors Dr J Robert Sneyd ����������������� Ms Susan James Prof Jan van der Meulen Prof Ruth Endacott Ms Tracey Harrison (from 1 Oct)

Trustee vacancies are advertised, as necessary, and ICNARC may also approach individuals thought to have the appropriate skills and experience. New Trustees spend time with members of the SMT and other staff, as part of their induction, to learn more about the organisation and to understand how they can add value through their skills and experience. Trustees are also encouraged to take part in training opportunities, are invited to attend the Annual Meetings for our national clinical audits and, where relevant, represent ICNARC on external advisory groups.

On appointment, each Trustee completes a Declaration of Interests form which is held in a Register of Interests and updated annually. All conflicts are actively managed through early identification of potential areas of conflict and actions taken to manage these, where relevant. There were no related party transactions in the 2020 financial year.

Public Benefit

In shaping the objectives and activities for each year, the Board of Management (Trustees) considers the guidance of the Charity Commission on public benefit, including the guidance ‘Public Benefit: Running a Charity’. The nature of ICNARC’s public benefit is detailed on pages 4-16 of this report.

We were pleased to appoint one new Trustees in October 2020, Ms Tracey Harrison who brings with her extensive business and financial experience and expertise.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 20

Senior Management Team

The Director and other members of the SMT are responsible for the day-to-day running of ICNARC under authority delegated to them by the Board of Management (Trustees) and are collectively responsible for the management and operations of ICNARC.

The SMT is responsible for implementing the strategy and policies, agreed with the Board of Management (Trustees), and operate on a threeyear, rolling review. The SMT proposes an annual Business Plan and operating budget, for approval by the Board of Management (Trustees) and monitors financial performance and organisational risk, accordingly.

Remuneration for SMT members is reviewed by Trustees and benchmarked to similar roles and organisations.

The SMT members serving during 2020 and into 2021 are:

Auditors/Bankers

Auditors MHA MacIntyre Hudson 2 London Wall Place London EC2Y 5AU

Bankers

Unity Trust Bank plc 9 Brindley Place Birmingham B1 2BR

Prof Kathryn Rowan Director

Prof David Harrison Head Statistician

Our staff

During 2020, ICNARC had an average paid workforce of 40 staff, located in our central London Office although during the pandemic largely working remotely from home.

ICNARC is an Equal Opportunities employer. We promote equality and diversity by:

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 21

Statement of Trustees’ responsibilities

Trustees’ responsibilities in relation to the financial statements

The Trustees (who are also Directors of the Intensive Care National Audit and Research Centre for the purposes of Company Law) are responsible for preparing the Report of the Directors and Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the Charitable Company and of the incoming resources and application of the resources, including the income and expenditure, of the Charitable Company for that period. In preparing those financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose, with reasonable accuracy at any time, the financial position of the Charitable Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charitable Company and, hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

In approving the Trustees’ Annual Report and Accounts in our capacity as Company Directors.

This report of the Trustees has been prepared taking advantage of the small companies exemption of section 415A of the Companies Act 2006.

Signed on behalf of the Board

Susan James Chair Date: 15 July 2021 Telephone: 020 7831 6878 Email: icnarc@icnarc.org Website: www.icnarc.org

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 22

Independent Auditors’ report to the Trustees of the Intensive Care National Audit and Research Centre

Opinion

We have audited the financial statements of Intensive Care National Audit and Research Centre (the ‘charitable company’) for the year ended 31 December 2020 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report.

We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Our evaluation of the Trustees’ assessment of the entity’s ability to continue to adopt the going concern basis of accounting included critical reviews of budgets and forecasts provided.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2020

Page 23

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the Trustees’ responsibilities statement included in the Trustees’ Annual Report, the Trustees (who are also the Directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 24

our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: https://www.frc.org.uk/Our-Work/Audit/Audit-and-assurance/Standards-andguidance/Standards-and-guidance-for-auditors/Auditors-responsibilities-for-audit/Description-of-auditorsresponsibilities-for-audit.aspx. This description forms part of our auditor’s report.

Use of this report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Rakesh Shaunak FCA (Senior Statutory Auditor) For and behalf of MHA MacIntyre Hudson Chartered Accountants and Statutory Auditors 6[th] Floor, 2 London Wall Place London, EC2Y 5AU

Date:

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 25

Statement of Financial Activities

(Incorporating an Income and Expenditure account) For the year ended 31 December 2020

Notes
Income from:
Charitable activities
Participants' Cost Contribution (Audits)
7
Activities in promoting the Audits
7
Other services
7
Research Grants
2
Total		 Restricted
2020
2019
General
Development
Fund
£
£
£
£
£
2,019,813
-
200,287
2,220,100
1,502,552
16,247
-
-
16,247
38,079
33,205
-
-
33,205
17,319
-
-
1,582,809
1,582,809
1,183,779
Unrestricted Funds
2,069,265
-
1,783,096
3,852,361
2,741,729
Expenditure on:
Charitable activities
Participants' Cost Contributions (Audits
5
Research
3
Total
5		 1,649,219
-
199,643
1,848,862
1,559,898
-
-
1,769,192
1,769,192
1,187,355
1,649,219
-
1,968,835
3,618,054
2,747,253
Net income/(expenditure)
Transfers between funds
18
Net movement in funds
Total funds brought forward
420,046
-
(185,738)
234,307
(5,524)
(451,965)
400,000
51,965
-
-
(31,920)
400,000
(133,773)
234,307
(5,524)
602,393
50,000
18,140
670,534
676,058
Total funds carried forward
18		 570,474
450,000
(115,633)
904,841
670,534

All ICNARC's operations are classified as continuing.

ICNARC had no recognised gains or losses other than those included in the movement in funds for the year.

A statement on the movement on reserves appears as Note 16 to the financial statements.

The Notes on pages 29 to 41 form part of these accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 26

Susan James, Chair

Formally approved by the Board of Management (Trustees) on 15 July 2021

The Notes on pages 29 to 41 form part of these accounts.

Company Registration Number: 02946727

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 27

Statement of Cash Flows

For the year ended 31 December 2020

Cash used in operating activities
(Increase)/Decrease in debtors
Increase/(Decrease) in creditors
Depreciation charges
Surplus/(Deficit) less interest income
Net cash used in operating activities
Cash flow from investing activities
Interest income
Purchase of tangible fixed assets
Net cash provided by investing activities
Cash flow from financing activities
Increase (decrease) in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at end year
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash in hand
ANALYSIS OF CHANGES IN NET DEBT		 2020
2019
(1,502,660)
59,130
728,964
(9,268)
319,256
60,257
234,307
(5,524)
(220,132)
104,595
-
-
(17,193)
(182,654)
(17,193)
(182,654)
-
-
(237,325)
(78,059)
1,442,458
1,520,517
1,205,133
1,442,458
2020
2019
£
£
1,205,133
1,442,458
1,205,133
1,442,458
Cash at bank and in hand At 1 January
2020
£
1,442,458
At 31 December
Cash flows
2020
£
£
(237,325)
1,205,133
1,442,458 (237,325)
1,205,133

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 28

Notes to the Accounts

For the year ended 31 December 2020

Intensive Care National Audit and Research Centre (ICNARC) is a private company limited by guarantee registered in England and Wales and an incorporated charity registered with the Charity Commission. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given on Page 20. The nature of the charity's operations and principal activities are detailed on pages 4-17. The charity is a public benefit entity as defined by FRS 102. The company registration is 2946727.

1 ACCOUNTING POLICIES

(a) The accounts have been prepared under the historical cost convention in accordance with the Companies Act 2006 and follow the recommendations in Accounting and Reporting by charities: Statement of Recommended Practices (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102).

(b) The financial statements are prepared on a going concern basis. The Board of Management (Trustees) have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure are sufficient with the level of reserves for the charity to be able to continue as a going concern. The financial impact of the COVID-19 pandemic on income has been reviewed and the projected cash flow, for the 24 months to December 2022, confirms that ICNARC has sufficient income to meet expenditure for the immediate and for the longer-term future. There has been no need to access ICNARC’s reserves during this period. The accounts are prepared in sterling, which is the functional and presentational currency of the charity, rounded to the nearest £1.

(c) Interest is accounted for when receivable.

(d) Research Grant income is recognised when the Charity has entitlement to the funds and any performance conditions have been met. Any advance income over expenditure is held on the Statement of Financial Position as deferred income.

(e) The Annual Participants Cost Contributions (APCC) is invoiced on the anniversary date of joining. Any proportion of a current year income relating to the following year is treated as deferred income.

(f) The NCAA participants income is invoiced on the anniversary date of joining. Any proportion of current year income relating to the following years is treated as deferred income.

(g) Resources expended are recognised in the period in which they occur. Resources expended include attributable VAT which cannot be recovered.

(h) Resources expended are allocated to specific activity where the costs relate directly to that activity. The cost of the overall direction and administration, comprising of salary and overhead costs are apportioned on an estimate of staff time and resources used to support those activities.

(i) All fixed assets are initially recorded at cost and capitalised if costs exceed £1,000.

(j) Depreciation is provided at the following annual rates to write off the cost of each asset on a straight-line basis over its estimated life. Rates currently used on cost are:

Office fabrication 20%
Computer equipment 33%
Office equipment 33%
Office furniture 20%

(k) IT development is capitalised as an intangible asset where there are expected to be economic benefits flowing to the charity from the asset and the amount can be reliably measured. However, when changing requirements indicate significant revisions and improvements are required, the asset will be written down to reflect this. When a decision is taken to capitalise software development the rate of amortisation will be matched to the anticipated useful life.

(l) Unrestricted funds are subscriptions and other incoming resources receivable or generated for the objects of the organisation without further specified purpose and are available as general funds.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 29

Notes to the Accounts For the year ended 31 December 2020 Continued

(m) Designated Funds are unrestricted funds earmarked by the Board of Management for a particular purpose (i.e. Development Fund).

(n) Restricted Funds are to be used for the specific purposes as laid down by the provider. Expenditure which meets these criteria is charged to the fund, together with a fair allocation of management and support costs.

(o) The charity operates a defined contribution pension scheme for its employees. The assets of the scheme are held separately from those of the charity. The annual contribution payable is charged to the income and expenditure account.

(p) Termination payments – Termination benefits, including redundancy costs, are recognized when the Charity has the obligation to pay the benefits and the can be reliably measured.

(q)Rentals applicable to operating leases where substantially all the benefits and risks of ownership remain with the lessor are charged in the income and expenditure account on a straight-line basis over the period of the lease. (r) The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. The financial assets and financial liabilities of the Charity are as follows:

Debtors – trade and other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 12. Prepayments and research project grant receivables are not financial instruments. Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – trade creditors, accruals and other creditors will be classified as financial instruments and are measured at amortised cost as detailed in Note 15. Taxation and social security are not included in the financial instruments’ disclosure. Deferred income is not deemed to be a financial liability, as the cash settlement has already taken place and there is simply an obligation to deliver charitable services rather than cash or another financial instrument. (s) The following judgments (apart from those involving estimates) have been made in the process of applying the above accounting policies that have had the most significant effect on amounts recognised in the financial statements:

· The allocation of managing and support costs to specific activity. The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year include:

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 30

Notes to the Accounts

For the year ended 31 December 2020

(continued)

2 RESEARCH GRANTS

Grants:
CTU Infrastructure - NIHR
FEVER - NIHR HTA
65 - NIHR HTA
Risk II - NIHR HTA
COAST - JGHT
COAST Nutrition - EDCTP
RRAM - NIHR HTA
REMAP-CAP (PREPARE) -
EC
Oxy-PICU - NIHR HTA
PICnIC - NIHR HTA
CAFE - NIHR HTA
FIRST -ABC - NIHR HTA
CIRCA - RC(UK)
PRESSURE
UK ROX
REMAP-CAP(Convalescent
Plasma)
GP Q Research -Welcome
& Nuffield
Other		 Restricted
General
Development
-
-
68,000
-
-
28,858
-
-
-
-
-
22,880
-
-
23,841
-
-
65,639
-
-
-
-
-
205,659
-
-
344,855
-
-
121,697
-
-
33,368
-
-
317,197
-
-
14,923
52,577
59,762
57,951
62,421
-
-
103,181
-
-
1,582,809
Unrestricted funds		 Total
Total
2020
2019
68,000
62,892
28,858
-
-
294,302
22,880
-
23,841
121,443
65,639
118,058
-
58,760
205,659
50,120
344,855
47,439
121,697
25,352
33,368
54,544
317,197
268,791
14,923
7,715
52,577
-
59,762
-
57,951
-
62,421
-
103,181
74,363
1,582,809
1,183,779

All research income in 2019, £1,183,779, was restricted.

3 RESTRICTED RESOURCES EXPENDITURE - RESEARCH

Start date
Grant value
CTU Infrastructure - NIHR
09/01/2013
£800,636
FEVER - NIHR HTA
11/01/2016
£516,030
65 - NIHR HTA
03/01/2016
£1,071,497
Risk II - NIHR HTA
08/01/2016
£261,240
COAST - JGHT
10/01/2016
£278,636
COAST Nutrition - EDCTP
05/01/2018
£800,636
RRAM - NIHR HTA
04/01/2018
£519,652
REMAP-CAP (PREPARE) - EC
01/01/2018
£284,772
Oxy-PICU - NIHR HTA
08/01/2019
£1,569,780
PICnIC - NIHR HTA
11/01/2019
£519,652
CAFE - NIHR HTA
02/01/2019
£298,562
FIRST -ABC - NIHR HTA
02/01/2019
£1,499,843
CIRCA - RC(UK)
06/01/2019
£70,719
PRESSURE
08/01/2020
£1,806,766
UK ROX
08/01/2020
£2,078,886
REMAP-CAP(Convalescent Plasma)
04/01/2020
£77,268
GP Q Research -Welcome & Nuffield
03/01/2020
£83,228
Other
various		 2020
2019
£
£
68,000
62,892
28,858
-
16,393
296,738
22,880
-
75,807
121,443
99,100
118,058
-
59,900
262,805
50,120
364,835
47,439
138,351
25,352
45,460
54,544
317,197
268,791
14,923
7,715
52,577
-
59,762
-
57,951
-
62,421
-
81,872
74,363
1,769,192
1,187,355

4 RESTRICTED RESOURCES EXPENDITURE - AUDIT

National Cardiac Arrest Audit

2020 2019
£ £
199,643 213,118

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 31

Notes to the Accounts

For the year ended 31 December 2020 (continued)

5 TOTAL EXPENDITURE

Staff costs
Training
Recruitment
IT Development
Meetings - Audit
Board of Management &
committees
Travel
Premises
Legal/audit fees
Communications
Publications/printing
Post and carriage
Bank charges
Depreciation
Research expenditure
Other costs
Allocation of support costs		 Unrestricted
Restricted
Total
Total
Audit
Promoting
Data
Services
Support
costs
Governanc
e
Audit
Research
grants
2020
2019
£
£
£
£
£
£
£
£
£
709,630
54,587
163,761
163,761
-
90,075
662,727
1,844,541
1,660,514
(502)
(39)
(116)
(116)
-
-
2,500
1,728
15,968
6,250
481
1,442
1,442
-
-
-
9,615
18,159
-
-
-
-
-
-
-
-
(55,592)
3,642
280
840
840
-
-
3,137
8,739
68,283
-
-
-
-
55
-
-
55
-
3,091
238
713
713
-
-
5,223
9,978
51,286
197,483
15,191
45,573
45,573
-
-
-
303,820
228,144
-
-
-
-
15,945
-
-
15,945
13,687
15,975
1,229
3,686
3,686
-
-
151
24,727
32,943
2,478
191
572
572
-
-
1,484
5,296
1,104
955
73
220
220
-
-
344
1,812
2,230
-
-
-
910
-
-
-
910
1,372
207,516
15,963
47,888
47,888
-
-
-
319,256
60,257
-
-
(44,626)
-
-
-
575,334
530,708
282,766
56,390
4,338
13,013
13,013
-
109,568
344,603
540,924
366,133
212,973
16,383
49,148
(278,504)
-
-
-
-
-
1,415,881
108,914
282,116
-
16,000
199,643
1,595,500
3,618,054
2,747,252

Allocation of support costs is the reallocated Management and Administration after deduction for Governance and on the basis of staff costs. Operating leases costs totalled £177,414 (£177,414 - 2019). See appendix 1 on page 39 for 2019 comparative note.

6 GOVERNANCE

6 GOVERNANCE
Board of Management & committees
Legal and HR
Financial		 Unrestricted
Restricted
2020
2019
£
£
£
£
55
-
55
6,946
8,445
-
8,445
8,858
7,500
-
7,500
4,829
16,000
-
16,000
20,633

Travel and meeting costs amounting to £55 (£6,946 - 2019) were reimbursed to 4 (9 - 2019) trustee members. Fees payable to the charity's auditors in respect of the audit and specialist advice were £7,500 (£4,590 - 2019). See appendix 2 on page 39 for 2019 comparative note.

7 INCOME

7 INCOME
Incoming resources for charitable activities include:
Audit Subscriptions deferred brought fwd
Audit Subscriptions received 2020
Less Audit Subscriptions deferred carried forward
Audit Subscriptions		 Unrestricted
Restricted
2020
2019
£
£
£
£
700,374
103,810
804,184
781,596
1,313,854
194,575
1,508,429
1,525,140
(640,582)
(98,098)
(738,680)
(804,184)
1,373,645 200,287
1,573,932
1,502,552
COVID-19 income
Activities in promoting Audits
Research Grants
Other services
Incoming resources for charitable activities include:		 646,168
16,247
-
33,205		 150,418
796,586
-
-
16,247
38,079
1,432,391
1,432,391
1,183,779
-
33,205
17,319
2,069,265 1,783,096
3,852,361
2,741,729

Activities in promoting Audits include: training £0 - (£6,175 - 2019) software licensing £14,637 - (£23,605 - 2019), meeting, travel funding and speaker fees £6,600 - (£8,299 - 2019) See appendix 3 on page 40 for 2019 comparative note.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 32

Notes to the Accounts

For the year ended 31 December 2020

(continued)

8 SURPLUS ON ORDINARY ACTIVITIES

Unrestricted
Restricted
£
£
319,256
-
7,650
-
The surplus is stated after charging:
Depreciation and amortisation
Auditors' remuneration		 2020
£
319,256
7,650		 2019
£
60,319
4,590
Auditors' remuneration -
prior year under accrual
2,250
-		 2,250 2,910
9 STAFF COSTS AND NUMBERS
Salaries
Social security costs
Pension
Seconded and agency staff		 2020
£
1,553,586
153,312
83,288
54,356		 2019
£
1,409,522
140,301
80,528
30,163
1,660,514
1,844,541
The number of employees receiving emoluments in excess of £60k:
£60,000 - £69,999		 1 3
£70,000 - £79,999 1 -
£80,000 - £89,000
£100,000 - £110,000		 -
-		 1
1
£110,000 - £120,000 1 -
The monthly average numbers employed during the year calculated on the basis of actual headcount:
Executive
Audit
Research
Statistics & IT Development
Operations		 No.
No.
1
1
10
11
10
7
11
11
8
8
40
38
No. No.
Executive 1 1
Audit 10 11
Research 10 7
Statistics & IT Development 11 11
Operations 8 8
40 38

The company operates a Group Personal Pension scheme. Contributions to the Group Personal Pension Scheme in 2020 were £83,288 (£80,528 in 2019).

The amount of pension contribution to higher paid staff in 2020 was £23,384 (£31,364 in 2019). The number of employees eligible to participate in the Group Personal Pension scheme at the end of 2020 is 44 (24 in 2019).

The number of employees auto-enrolled at the end of 2020 is 13 (17 in 2019).

The Trustees and the joint Directors are the key management personnel of the company. The Trustees, being in a voluntary position, receive no remuneration from the organisation (2019 Nil). The Director received total emoluments of £136,963 (2019: Joint Directors - £193,620).

Total salaries for 2020 includes £2,152 of contractual redundancy costs (2019: £Nil).

10 TAXATION

The company is exempt from income and corporation taxes under S466 to S493 Corporation Tax Act 2010 (CTA 2010).

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 33

Notes to the Accounts For the year ended 31 December 2020

(continued)

11 TANGIBLE FIXED ASSETS
Cost at 1 January 2020
Additions
Disposals
At 31 December 2020
Depreciation at 1 January 2020		 Office
Computer
Office
Office
fabrication
equipment
equipment
furniture
Total
£
£
£
£
£
47,792
141,529
20,084
55,415
264,820
1,668
15,525
17,193
-
-
-
-
49,460
157,054
20,084
55,415
282,013
19,144
102,399
20,084
36,585
178,212
Depreciation for the period 28,245
41,979
7,436
77,660
Disposals
At 31 December 2020		 -
-
-
-
47,389
144,378
20,084
44,021
255,872
Net book value at 31 December 2020 2,071
12,676
11,394
26,141
Net book value at 31 December 2019
11a INTANGIBLE ASSETS
Cost at 1 January 2020
Additions
Disposals
At 31 December 2020
Amortisation at 1 January 2020
Amortisation for the period
Disposals
At 31 December 2020
Net book value at 31 December 2020
Net book value at 31 December 2019		 28,648
39,130
-
18,830
86,608
Software
IT
Development
Total
£
£
£
45,400
248,521
293,921
-
-
-
-
-
45,400
248,521
293,921
32,537
19,787
52,324
12,863
228,734
241,597
-
-
-
45,400
248,521
293,921
-
-
-
12,863
228,734
241,597

Amortisation: Third Party Computer Software is provided at an annual rate of 33%

IT Development relates to investment in Platform X, our new database platform. This value has been written down to reflect need for ongoing improvements.

12 DEBTORS
Trade debtors
Other debtors
Research projects		 Unrestricted
Restricted
2020
2019
£
£
£
£
1,372,280
-
1,372,280
345,759
-
-
-
30,607
-
1,211,262
1,211,262
754,605
Prepayments 127,390
-
127,390
77,301
1,499,670
1,211,262
2,710,932
1,208,272

See appendix 4 on page 40 for 2019 comparative note.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 34

Notes to the Accounts

For the year ended 31 December 2020

(continued)

13 CREDITORS £
£		 2020
2019
£
£
Trade creditors
Other creditors
Accruals
Taxation & Social Security
Deferred income (note 14)		 145,340
-
17,064
-
72,845
1,221,293
226,035
-
824,988
404,801		 145,340
66,034
17,064
14,347
1,294,138
1,084,270
226,035
108,734
1,229,788
1,035,015
1,286,270
1,626,094		 2,912,364
2,308,400

See appendix 5 on page 40 for 2019 comparative note.

14 CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR

14 CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR
Dilapidations 2020
2019
£
£
75,000
-
75,000
-

The dilapidation provision recognises the obligation to restore existing offices to their original state at the end of the lease in March 2022.

15 PROVISIONS FOR LIABILITIES
VAT Review		 2020
2019
£
£
50,000
-
50,000
-

Despite work carried out in 2020 and 2021 to reconcile prior VAT liabilities, the provision for VAT reflects the potential for VAT

16 DEFERRED INCOME

Deferred income comprises audit and research income payable annually and income deferred in the Clinical infrastructure fund.

Balance at 1st January 2020
Amount released to incoming resources
Deferred audit
Deferred clinical infrastructure
Deferred research
Deferred other
Balance at 31 December 2020		 2020
2019
£
£
1,035,015
897,151
(1,035,015)
(897,151)
738,680
804,184
17,000
40,020
289,703
190,811
184,405
-
1,229,788
1,035,015

Deferred other relates to COVID-19 income received in advance.

17 ANALYSIS OF NET ASSETS BETWEEN FUNDS

Fixed assets
Current assets
Creditors due within one year
Creditors due more than one year		 Restricted
2020
2019
General
Designated
Funds
£
£
£
£
£
26,141
-
-
26,141
328,205
1,955,605
450,000
1,510,461
3,916,066
2,650,729
(1,286,272)
-
(1,626,094)
(2,912,366)
(2,308,400)
(125,000)
-
-
(125,000)
-
Unrestricted Funds
570,474
450,000
(115,633)
904,841
670,534

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 35

Notes to the Accounts

For the year ended 31 December 2020

(continued)

18 RESERVES

The movement in the reserves were as follows:

18 RESERVES
The movement in the reserves were as follows:
At 1 Jan
At 31 Dec
Restricted Funds
Research Grants:		 2020
Income
Expenditure
Transfers
2020
£
£
£
£
£
CTU Infrastructure - NIHR 68,000
(68,000)
-
28,858
(28,858)
-
(2,436)
-
(16,393)
(18,829)
22,880
(22,880)
-
23,841
(75,807)
51,965
-
65,639
(99,100)
(33,461)
(1,140)
-
-
(1,140.00)
205,659
(262,805)
(57,146)
344,855
(364,835)
(19,980)
121,697
(138,351)
(16,654)
33,368
(45,460)
(12,093)
317,197
(317,197)
-
14,923
(14,923)
-
52,577
(52,577)
-
59,762
(59,762)
-
57,951
(57,951)
-
62,421
(62,421)
-
103,181
(81,872)
21,309
FEVER - NIHR HTA
65 - NIHR HTA
Risk II - NIHR HTA
COAST - JGHT
COAST Nutrition - EDCTP
RRAM - NIHR HTA
REMAP-CAP (PREPARE) - EC
Oxy-PICU - NIHR HTA
PICnIC - NIHR HTA
CAFE - NIHR HTA
FIRST -ABC - NIHR HTA
CIRCA - RC(UK)
PRESSURE
UK ROX
REMAP-CAP(Convalescent Plasma)
GP Q Research -Welcome & Nuffield
Other
Total grants (3,576)
1,582,809
(1,769,192)
51,965
(137,993)
Audit:
National Cardiac Arrest Audit 21,716
200,287
(199,643)
22,360
Total Restricted Funds 18,140
1,783,096
(1,968,835)
51,965
(115,633)
Unrestricted Funds
Development Fund (designated)
General Fund		 50,000
-
-
400,000
450,000
602,393
2,069,265
(1,649,219)
(451,965)
570,474
At the end of the year 652,393
2,069,265
(1,649,219)
(51,965)
1,020,474
670,534
3,852,361
(3,618,054)
-
904,841

Purposes of restricted funds

Resourced against awarded scientific research grants. At times income is received in advance of expenditure. Some funding for research projects do not provide sufficient monies to cover all costs, including overheads, and result in a deficit being incurred.

When such deficits arise they will be balanced from general funds on completion of the project if the deficit is not corrected prior to completion.

Purpose of designated funds

The Development Fund has been increased by £400,000 in 2020 to provide sufficient resources for the ongoing development of the platform to collate and analyse national and comparative data for the audit of patient outcome for intensive care and high dependency care and the associated research therein. It will be expended over the next 2 years.

See appendix 6 on page 41 for 2019 comparative note.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 36

Notes to the Accounts

For the year ended 31 December 2020

(continued)

19 RELATED PARTY TRANSACTIONS

There are no related party transactions in the year (£0 - 2019) that require disclosure other than the Trustees' expenses in note 6.

20 ULTIMATE CONTROLLING PARTY

The Trustees are of the opinion that there is no one controlling party of the charitable company.

21 PENSION COMMITMENTS

The Charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £83,288 (2019: £80,528). Contributions totalling £15,192 (2019: £14,347) were payable to the fund as at 31 December 2020 and included in the Statement of Financial Position.

22 OPERATING LEASE COMMITMENTS

The total future minimum lease payments under non-recoverable operating leases for land, buildings and equipment are shown below, analysed according to the expiry date of the lease.

Land and buildings
Within one year
Between one and two years
Between three and five years
Equipment
Within one year
Between one and two years
Between two and five years
Total		 2020
2019
£
£
169,983
169,983
42,496
169,983
-
42,496
212,479
382,462
2,378
3,072
2,378
2,378
3,567
6,142
8,323
11,592
220,802
394,054

23 CAPITAL COMMITMENTS

The next stage of ICNARC's infrastructure projects commences in 2021 with the establishment of a new Data and Data Services team and upgrades and new developments of the IT Platform at an estimated future costs of circa £450,000. Funds to support this project have been designated.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 37

Notes to the Accounts For the year ended 31 December 2020

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 38

Notes to the Accounts For the year ended 31 December 2019 Continued

APPENDICES

2019 Comparatives

Appendix 1

Allocation of support costs is the reallocation Management and Administration after deduction for Governance on the basis of staff costs. Operating leases costs totalled £177,414 (£179,272 - 2018).

Appendix 2

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 39

Appendix 3

Activities in promoting APCC include: training £6,175 - (£3,291 - 2018) software licensing £23,605 - (£19,418 - 2018), meeting, travel funding and speaker fees £8,299 - (£13,375 - 2018)

Appendix 4

Appendix 5

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 40

Appendix 6

18 RESERVES

The movement in the reserves were as follows:

At 1 Jan
At 31 Dec
Restricted Funds
Research Grants:		 2019
Income
Expenditure
Transfers
2019
£
£
£
£
£
CIF - NIHR
65 - NIHR HTA
Risk II - NIHR HTA
COAST - JGHT
COAST Nutrition - EDCTP
RRAM - NIHR HTA
REMAP-CAP (PREPARE) -
EC
Oxy-PICU - NIHR HTA
PICnIC - NIHR HTA
CAFE - NIHR HTA
FIRST -ABC - NIHR HTA
CIRCA - RC(UK)		 -
62,892
(62,892)
-
-
-
294,302
(296,738)
-
(2,436)
-
-
-
-
-
121,443
(121,443)
-
-
-
118,058
(118,058)
-
-
-
58,760
(59,900)
-
(1,140)
-
50,120
(50,120)
-
-
-
47,439
(47,439)
-
-
-
25,352
(25,352)
-
-
-
54,544
(54,544)
-
-
-
268,791
(268,791)
-
-
-
7,715
(7,715)
-
-
Other -
74,363
(74,363)
-
-
Total grants -
1,183,779
(1,187,355)
-
(3,576)
Audit:
National Cardiac Arrest Audit 26,263
208,572
(213,119)
-
21,716
Total Restricted Funds
Unrestricted Funds
Development Fund (designated)
General Fund
At the end of the year		 26,263
1,392,351
(1,400,473)
-
18,140
50,000
-
-
-
50,000
599,795
1,349,378
(1,346,779)
-
602,393
649,795
1,349,378
(1,346,779)
-
652,393
676,058
2,741,729
(2,747,252)
-
670,534

Purposes of restricted funds

Resourced against awarded scientific research grants. At times income is received in advance of expenditure. The modest deficits on Trial 65 and RRAM are due to timing and are covered provisionally by the general fund. These are ongoing projects and these deficits will be balanced in the year ending 31 December 2020.

Purpose of designated funds

The Development Fund has been established to assist the development of a national, comparative, audit of patient outcome for intensive care and high dependency care and the associated research therein. It will be expended in the year ending 31 December 2020.

Intensive Care National Audit and Research Centre | Annual Report and Accounts 2019

Page 41